Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21921223 | 0.93 | PTPN11 (0.71) | PTPN11KCNH2EGFR | |
| SCHEMBL30683754 | 0.93 | PTPN11 (0.71) | PTPN11KCNH2EGFR | |
| SCHEMBL24704103 | 0.93 | PTPN11 (0.71) | PTPN11KCNH2EGFR | |
| SCHEMBL30683768 | 0.90 | PTPN11 (0.60) | PTPN11KCNH2EGFR | |
| SCHEMBL21921037 | 0.90 | PTPN11 (0.60) | PTPN11KCNH2EGFR | |
| SCHEMBL23024349 | 0.90 | PTPN11 (0.60) | PTPN11KCNH2EGFR | |
| SCHEMBL29550546 | 0.90 | PTPN11 (0.60) | PTPN11KCNH2EGFR | |
| SCHEMBL30950325 | 0.86 | PTPN11 (0.58) | PTPN11KCNH2EGFR | |
| SCHEMBL24034352 | 0.86 | PTPN11 (0.59) | PTPN11KCNH2EGFR | |
| SCHEMBL23046214 | 0.86 | PTPN11 (0.67) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
| WO-2020063760-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | PTPN11 10/4885KCNH2 4388/4885EGFR 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.